



Content highlights

Release date

November 2024

Updated throughout the year to reflect Clarivate's expert analysis of the latest major-market events

Geography

United States, EU5, Japan

Primary research

25 country-specific interviews with thought-leading neurologists

Supported by survey data collected for this and other Clarivate research

Epidemiology

Diagnosed and drug-treated prevalent cases of PD by country

Forecast

10-year, annualized, drug-level sales and patient share of key PD therapies through 2033, segmented by brands / generics

Drug treatments

Coverage of key current and emerging therapies

Parkinson's Disease

Spotlight on Disease Landscape & Forecast

Market outlook

In the dynamic Parkinson's disease (PD) market, recent advancements have been matched by notable challenges. Although the introduction of new brands, including Acorda's Inbrija and AbbVie's Vyalev / Produodopa, has broadened the spectrum of available treatments, the market has faced setbacks. For instance, Sunovion withdrew Kynmobi from the market and Ongentys experienced a temporary discontinuation. Further, promising therapies like Supernus's SPN-830 and Amneal's IPX-203 have encountered regulatory hurdles delaying their launch. As developers seek to establish a niche for their products, the treatment algorithm will become more complex. While new brands can drive market value, intense competition and patient and payer cost sensitivity in a predominantly generic drug market make for a challenging launch environment. With generic alternatives available in all PD drug classes, new brands that lack clinical differentiation will have difficulty competing. A thorough grasp of current and future PD market dynamics is crucial for both new and established players vying for a share of this increasingly competitive landscape.

Questions answered

- What will be the clinical and commercial impact of newly launched and emerging levodopa reformulations (i.e., Vyalev / Produodopa, ND-0612, and IPX203)?
- How do neurologists view the clinical prospects for emerging adjunctive therapies for motor fluctuations, dyskinesia, and dementia?
- Which putative disease-modifying therapies are most promising?
- How are neurologists incorporating acute rescue therapies for "off" periods, and which unmet needs remain for other novel therapies targeting motor symptoms in PD?

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.

Key features

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Learn more about Clarivate's full suite of Parkinson's disease solutions:

healthcare.support@clarivate.com | clarivate.com